Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Loupakis, Fotios ^a,b   Cremolini, Chiara ^b   Yang, Dongyun ^a   Salvatore, Lisa ^b   Zhang, Wu ^a   Wakatsuki, Takeru ^a   Bohanes, Pierre ^a   Schirripa, Marta ^b   Benhaim, Leonor ^a   Lonardi, Sara ^c   Antoniotti, Carlotta ^b   Aprile, Giuseppe ^d   Graziano, Francesco ^e   Ruzzo, Annamaria ^f   Lucchesi, Sara ^g   Ronzoni, Monica ^h   de Vita, Ferdinando ⁱ   Tonini, Giuseppe ^j   Falcone, Alfredo ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITY OF URBINO   (Italy)

^g ISTITUTO TOSCANO TUMORI   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BEVACIZUMAB; CYSTEINE; DNA; FLUOROURACIL; FOLINIC ACID; GLYCINE; IRINOTECAN; OXALIPLATIN; THREONINE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA EXTRACTION; DNA SEQUENCE; EPAS1 GENE; FEMALE; GENETIC VARIABILITY; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; VEGF GENE; VEGFA GENE; VEGFR GENE; VEGFR1 GENE; VEGFR2 GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FLUOROURACIL; GENE EXPRESSION; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84879803703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066774     Document Type: Article

References (25)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-42.
2. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539-44.
3. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, et al. (2012) Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J Clin Oncol 30(28): 3499-506.
4. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863): 303-12.
5. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6): 327-38.
6. Bocci G, Loupakis F, (2011) Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics 12(8): 1077-80.
7. Lu P, Weaver VM, Werb Z, (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4): 395-406.
8. Carmeliet P, Jain RK, (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6): 417-27.
9. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-8.
10. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, et al. (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11: 247.
11. Pander J, Wessels JA, Gelderblom H, van der Straaten T, Punt CJ, et al. (2011) Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 22(5): 1147-53.
12. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, et al. (2011) Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17(17): 5783-92.
13. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, et al. (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 14(22): 7554-63.
14. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, et al. (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13(7): 724-33.
15. Lambrechts D, Delmar P, Miles DW, Leighl N, Saltz L, et al. (2011) Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab. Eur J Canc 47(S1): S173.
16. Tejpar S, Prenen H, Mazzone M, (2012) Overcoming resistance to antiangiogenic therapies. Oncologist 17(8): 1039-50.
17. Bottsford-Miller JN, Coleman RL, Sood AK, (2012) Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies. J Clin Oncol 30(32): 4026-34.
18. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, et al. (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 26(2): 183-9.
19. Sargent DJ, Conley BA, Allegra C, Collette L, (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9): 2020-7.
20. Mandrekar SJ, Sargent DJ, (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27(24): 4027-34.
21. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A, (2010) Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol (76):: 309-17.
22. Liu L, Wu C, Wang Y, Zhong R, Wang F, et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis. 32(3): 336-42.
23. Zhong R, Liu L, Zou L, Sheng W, Zhu B, et al. (2013) Genetic variations in the TGFβ signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis. 34(4): 936-42.
24. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14(1): 29-37.
25. Masi G, Loupakis F, Salvatore L, Cremolini C, Fornaro L, et al. (2012) Randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 23(s9): ixe9.